WBR0421: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor={{Rim}}
|QuestionAuthor={{Rim}}, {{AJL}} {{Alison}}
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Biochemistry
|MainCategory=Biochemistry
Line 20: Line 20:
|MainCategory=Biochemistry
|MainCategory=Biochemistry
|SubCategory=Endocrine
|SubCategory=Endocrine
|Prompt=A 17-year-old female presents to the emergency room with chest pain and dyspnea at rest.  The patient takes atorvastatin for hypercholesterolemia and multiple members of her family died at a young age from myocardial infarction.  Upon physical examination, you note tendon xanthomas on the Achilles tendon and arcus senilis corneae on the outer margin of the iris. Vital signs illustrate a temperature of 37 °C, heart rate of 102 beats per minute, and blood pressure of 110/70 mmHg.  An electrocardiogram (ECG) reveals ST-segment elevation in the anterior leads, elevation of tropnin I levels, and low density lipoprotein-cholesterol (LDL-C) levels of 980 mg/dL. Which of the following explains the pathogenesis of this patient’s disease?
|Prompt=A 17-year-old female presents to the emergency room with complaints of chest pain and shortness of breath at rest.  The patient takes atorvastatin for hypercholesterolemia and multiple members of her family died at a young age from myocardial infarction.  Upon physical examination, you note tendon xanthomas on the Achilles tendon and arcus senilis corneae on the outer margin of the iris. Vital signs illustrate a temperature of 37 °C, heart rate of 102 beats per minute, and blood pressure of 110/70 mmHg.  An electrocardiogram (ECG) reveals ST-segment elevation in the anterior leads, elevation of tropnin I levels, and low density lipoprotein-cholesterol (LDL-C) levels of 980 mg/dL. Which of the following explains the pathogenesis of this patient’s disease?


|Explanation=[[Familial hypercholesterolemia]] (FH) is an autosomal dominant inherited disease characterized by the deficiency of [[LDL]] receptors on the hepatocytes plasma membrane due to a mutation of LDLR gene on chromosome 19.  The mutation results in abnormally elevated amounts of serum LDL due to decreased clearance of LDL at the level of the liver; predisposing affected patients to accelerating [[atherosclerosis]] at a young age with increased risk of cardiovascular disease, such as [[myocardial]] [[infarction]], and signs of [[hypercholesterolemia]] on physical exam, such as [[Achilles tendon xanthoma]] and [[arcus senilis corneae]], as described in the patient in the vignette.  
|Explanation=[[Familial hypercholesterolemia]] (FH), an autosomal dominant disease characterized by the deficiency of [[LDL]] receptors on the hepatocytes plasma membrane, results from a mutation of LDLR gene on chromosome 19.  The mutation results in abnormally elevated amounts of serum LDL due to decreased clearance of LDL at the level of the liver. Affected patients are predisposed to accelerated [[atherosclerosis]] and an increased risk of cardiovascular diseases, such as [[myocardial]] [[infarction]], and [[hypercholesterolemia]] manifesting upon physical exam as [[Achilles tendon xanthoma]] and [[arcus senilis corneae]].  
FH has a homozygous form and a heterozygous form.  The homozygous form is more severe; it occurs in patients who have 2 mutated alleles of the gene.  Classically, patients with homozygous mutation have LDL levels approximately 1000 mg/dL that are often refractory to anti-lipidemic medications with cardiovascular complications that can occur as early as during childhood. Heterozygous form occurs when 1 mutated allele is inherited.  In the heterozygous form, LDL levels are classically lower than that of homozygous FH, in the range of 300-500 mg/dL.  In heterogeneous FH, symptoms may not occur as early as homogeneous FH but the risk of atherosclerosis is still high when compared to the general population.
FH occurs in both a homozygous and a heterozygous form.  The homozygous form, which is more severe, often manifests with LDL levels approximately 1000 mg/dL that are often refractory to anti-lipidemic medications and cardiovascular complications that frequently occur during childhood. In the heterozygous form, LDL levels are classically lower than that of homozygous FH, ranging from 300-500 mg/dL.  In patients with heterogeneous FH, who often do not display symptoms during childhood, the risk of atherosclerosis is elevated relative to the general population.


|EducationalObjectives=  
|EducationalObjectives= FH, an autosomal dominant disease resulting from a mutation of LDLR gene on chromosome 19, frequently leads to a deficiency or absence of LDL receptors on hepatocytes.  FH manifest with both a heterozygous and a more severe homozygous form.  FH may manifest with atherosclerosis in young individuals, as well as with signs of hypercholesterolemia, predisposing those affected to myocardial infarctions.
FH is a genetic autosomal dominant disease caused by a mutation of LDLR gene on chromosome 19 that causes deficiency or absence of LDL receptors on hepatocytes.  FH has a heterozygous and a more severe homozygous form.  FH causes atherosclerosis in young individuals and signs of hypercholesterolemia, predisposing affected individuals to myocardial infarctions.


|References=
|References= Motulsky AG. Genetic aspects of familial hypercholesterolemia and its diagnosis. Arteriosclerosis. 1989; Jan-Feb;9(1 Suppl):I3-7
Motulsky AG. Genetic aspects of familial hypercholesterolemia and its diagnosis. Arteriosclerosis. 1989; Jan-Feb;9(1 Suppl):I3-7


|AnswerA=Increased hepatocyte production of LDL
|AnswerA=Increased hepatocyte production of LDL
|AnswerAExp=Increased hepatocytes production of LDL is not the pathogenesis of FH.  LDL production is increased secondary to insulin resistance and diabetes mellitus, renal disease, and in obese individuals.
|AnswerAExp=The increased hepatocytes production of LDL is not the pathogenesis of FH.  LDL production is frequently increased secondary to insulin resistance, [[diabetes mellitus]], renal disease, and in obese individuals.
|AnswerB=LDL-receptor overexpression
|AnswerB=LDL-receptor overexpression
|AnswerBExp=LDL receptor over-expression occurs with statin therapy secondary to decreased production of cholesterol by inhibition of HMG-CoA reductase.  In this case, the risk of atherosclerosis is expected to be reduced.
|AnswerBExp=LDL receptor over-expression, occurring upon statin therapy secondary to decreased production of cholesterol by inhibition of HMG-CoA reductase, results in a reduced risk of [[atherosclerosis]].
|AnswerC=Deficiency of high density lipoprotein (HDL)
|AnswerC=Deficiency of high density lipoprotein (HDL)
|AnswerCExp=Deficiency of HDL is a genetic mutation of the ABC1 gene.  It might cause Tangier disease (TD) and some types of hypoalphalipoproteinemia (HA), both of which are characterized by low HDL.  HDL is considered an inverse predictor of atherosclerosis.  However, the patient’s work-up in the vignette showed abnormally elevated serum LDL levels, suggestive of FH.
|AnswerCExp=Deficiency of HDL, frequently resulting from a genetic mutation of the ABC1 gene, may cause [[Tangier disease]] (TD) and some types of [[hypoalphalipoproteinemia]] (HA).  HDL is considered an inverse predictor of [[atherosclerosis]].   
|AnswerD=Deficiency of LDL receptors on hepatocyte plasma membrane
|AnswerD=Deficiency of LDL receptors on hepatocyte plasma membrane
|AnswerDExp=FH is characterized by myocardial infarction at young age.  FH is caused by a mutation of the LDL receptor at the hepatocytes with abnormally elevated levels of circulating LDL.
|AnswerDExp=See explanation.  
|AnswerE=Deficiency of lipoprotein lipoprotein lipase (LPL)
|AnswerEExp=Deficiency of lipoprotein lipase (LPL), characteristic of [[type I dyslipidemia]] ([[hyperchylomicronemia]]), manifests with elevated levels of circulating chylomicrons, resulting in elevated levels of triglycerides and cholesterol. A frequent complication of [[hyperchylomicronemia]] is recurrent [[pancreatitis]], not myocardial infarction.
|AnswerEExp=Deficiency of lipoprotein lipase (LPL) is type I dyslipidemia, called hyperchylomicronemia, which is characterized by elevated levels of circulating chylomicrons causing high levels of triglycerides and cholesterol.   Although eruptive xanthoma can be present in hyperchylomicronemia, a classic complication of hyperchylomicronemia is usually recurrent pancreatitis, not myocardial infarction.
|RightAnswer=D
|RightAnswer=D
|WBRKeyword=LDL, familial, hypercholesterolemia, myocardial, infarction
|WBRKeyword=LDL, familial hypercholesterolemia, myocardial, infarction, genetics, autosomal dominant, FH, inheritance
|Approved=No
|Approved=Yes
}}
}}

Revision as of 14:01, 21 July 2014

 
Author [[PageAuthor::Rim Halaby, M.D. [1], Alison Leibowitz [2] (Reviewed by Alison Leibowitz)]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Biochemistry
Sub Category SubCategory::Endocrine
Prompt [[Prompt::A 17-year-old female presents to the emergency room with complaints of chest pain and shortness of breath at rest. The patient takes atorvastatin for hypercholesterolemia and multiple members of her family died at a young age from myocardial infarction. Upon physical examination, you note tendon xanthomas on the Achilles tendon and arcus senilis corneae on the outer margin of the iris. Vital signs illustrate a temperature of 37 °C, heart rate of 102 beats per minute, and blood pressure of 110/70 mmHg. An electrocardiogram (ECG) reveals ST-segment elevation in the anterior leads, elevation of tropnin I levels, and low density lipoprotein-cholesterol (LDL-C) levels of 980 mg/dL. Which of the following explains the pathogenesis of this patient’s disease?]]
Answer A AnswerA::Increased hepatocyte production of LDL
Answer A Explanation [[AnswerAExp::The increased hepatocytes production of LDL is not the pathogenesis of FH. LDL production is frequently increased secondary to insulin resistance, diabetes mellitus, renal disease, and in obese individuals.]]
Answer B AnswerB::LDL-receptor overexpression
Answer B Explanation [[AnswerBExp::LDL receptor over-expression, occurring upon statin therapy secondary to decreased production of cholesterol by inhibition of HMG-CoA reductase, results in a reduced risk of atherosclerosis.]]
Answer C AnswerC::Deficiency of high density lipoprotein (HDL)
Answer C Explanation [[AnswerCExp::Deficiency of HDL, frequently resulting from a genetic mutation of the ABC1 gene, may cause Tangier disease (TD) and some types of hypoalphalipoproteinemia (HA). HDL is considered an inverse predictor of atherosclerosis.]]
Answer D AnswerD::Deficiency of LDL receptors on hepatocyte plasma membrane
Answer D Explanation AnswerDExp::See explanation.
Answer E AnswerE::
Answer E Explanation [[AnswerEExp::Deficiency of lipoprotein lipase (LPL), characteristic of type I dyslipidemia (hyperchylomicronemia), manifests with elevated levels of circulating chylomicrons, resulting in elevated levels of triglycerides and cholesterol. A frequent complication of hyperchylomicronemia is recurrent pancreatitis, not myocardial infarction.]]
Right Answer RightAnswer::D
Explanation [[Explanation::Familial hypercholesterolemia (FH), an autosomal dominant disease characterized by the deficiency of LDL receptors on the hepatocytes plasma membrane, results from a mutation of LDLR gene on chromosome 19. The mutation results in abnormally elevated amounts of serum LDL due to decreased clearance of LDL at the level of the liver. Affected patients are predisposed to accelerated atherosclerosis and an increased risk of cardiovascular diseases, such as myocardial infarction, and hypercholesterolemia manifesting upon physical exam as Achilles tendon xanthoma and arcus senilis corneae.

FH occurs in both a homozygous and a heterozygous form. The homozygous form, which is more severe, often manifests with LDL levels approximately 1000 mg/dL that are often refractory to anti-lipidemic medications and cardiovascular complications that frequently occur during childhood. In the heterozygous form, LDL levels are classically lower than that of homozygous FH, ranging from 300-500 mg/dL. In patients with heterogeneous FH, who often do not display symptoms during childhood, the risk of atherosclerosis is elevated relative to the general population.
Educational Objective: FH, an autosomal dominant disease resulting from a mutation of LDLR gene on chromosome 19, frequently leads to a deficiency or absence of LDL receptors on hepatocytes. FH manifest with both a heterozygous and a more severe homozygous form. FH may manifest with atherosclerosis in young individuals, as well as with signs of hypercholesterolemia, predisposing those affected to myocardial infarctions.
References: Motulsky AG. Genetic aspects of familial hypercholesterolemia and its diagnosis. Arteriosclerosis. 1989; Jan-Feb;9(1 Suppl):I3-7]]

Approved Approved::Yes
Keyword WBRKeyword::LDL, WBRKeyword::familial hypercholesterolemia, WBRKeyword::myocardial, WBRKeyword::infarction, WBRKeyword::genetics, WBRKeyword::autosomal dominant, WBRKeyword::FH, WBRKeyword::inheritance
Linked Question Linked::
Order in Linked Questions LinkedOrder::